Med24
peptide-development 21. 9. 2026 • 2 min read • Diabetes, obesity & metabolism

Real-World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in FAERS

Background Both the GLP-1 receptor agonist semaglutide and the novel dual GIP/GLP-1 receptor agonist tirzepatide have emerged as first-line therapeutic options for metabolic diseases. However, their real-world comparative safety profiles are difficult to interpret due to differential reporting composition in...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This study compared adverse event (AE) reporting patterns of tirzepatide and semaglutide using data from the FAERS spontaneous reporting database. The analysis covered reports from May 2022 to June 2026.

Key Clinical Findings

A total of 151,654 tirzepatide reports and 64,987 semaglutide reports were examined. The study investigated how reporter identity – specifically, the distinction between general population and healthcare professional (HCP) reporters – influenced the prominence of reported signals. Four methods were used to determine signal convergence, alongside the Benjamini-Hochberg false discovery rate procedure to ensure signal robustness. Comparisons were made using the ratio of reporting odds ratios (RORR) with 95% confidence intervals.

Sponsored content

Differential Reporting Patterns

In the general population, only semaglutide met the stringent four-method criteria for gastrointestinal (GI) and metabolic disorders, with RORR values of 0.58 and 0.59 respectively. Pancreatitis signals were observed for both agents, but the difference attenuated within the Type 2 Diabetes Mellitus (T2DM) indication. Diabetic ketoacidosis signals were exclusively reported for semaglutide in the HCP cohort, with a RORR of 3.52. Tirzepatide demonstrated higher reporting of hypoglycaemia, with a RORR of 1.91. Within the HCP cohort, tirzepatide’s GI RORR increased to 2.53, and semaglutide exhibited signals for eye disorders with a RORR of 2.61. All sensitivity analyses, including stratification by indication, seriousness, geography, and calendar quarter, confirmed the directional stability of these comparative reporting patterns across various subgroups. The findings highlight distinct AE reporting patterns between the two agents, influenced by reporter type. These results are considered hypothesis-generating and require further confirmation with defined exposure denominators.

Original Scientific Source
Diabetes, obesity & metabolism
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort
peptide-development

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

While GLP-1 and GIP receptor agonists like semaglutide and tirzepatide have revolutionized pharmacologic obesity treatment, metabolic and bariatric surgery (MBS) continues to demonstrate superior weight loss and cost-effectiveness. Current evidence shows tirzepatide outperforms semaglutide with over 20% weight...

1. 12. 2026 Read article →
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
peptide-development

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits...

10. 11. 2026 Read article →
The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome
peptide-development

The Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), affects 170 million women globally and is often accompanied by obesity and various levels of insulin resistance. Incretin-based therapies, including the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and...

23. 10. 2026 Read article →
Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
peptide-development

Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review

Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence...

16. 10. 2026 Read article →
Advertisement